



In Conversation with the Neighborhood Hepatologist: Practical Strategies for Improving Diagnosis & Risk Stratification of MASLD

Organizational Resources

Websites

[American Association for the Study of Liver Diseases \(AASLD\)](#)

Studies and References

Epidemiology

[Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease; Estes C et al. Hepatology 2018 Jan;67\(1\):123-133.](#)

Co-morbidities

[AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise; Younossi ZM et al. Gastroenterology. 2021;160\(3\):912-918](#)

[Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach; Targher G. Et al. Lancet Gastroenterol Hepatol. 2021 Jul;6\(7\):578-588.](#)

Liver fibrosis - most important predictor of poor outcomes in patients with MASH

[Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease; Sanyal AJ et al. NEJM, 2021 Oct 21;385\(17\):1559-1569.](#)

[Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort; Simon TG et al. Gut. 2022 Sep;71\(9\):1867-1875.](#)

[Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease; Angulo P et al. Gastroenterology. 2015 Aug;149\(2\):389-97.e10](#)

[Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis; Sanyal AJ et al. Hepatology. 2022 May;75\(5\):1235-1246](#)

Diagnosis

[Liver fibrosis scores predict liver disease mortality in the United States population; Unalp Arida A, et al. Hepatology. 2017 Jul;66\(1\):84-95.](#)

[Fibrosis-4 Index Can Independently Predict Major Adverse Cardiovascular Events in Nonalcoholic Fatty Liver Disease; Viera JV et al. Am J Gastroenterol. 2022 Mar 1;117\(3\):453-461](#)

Clinical Practice Guidelines and Goals of Managing MASH

[AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease; AASLD Practice Guidance Hepatology. 2023 May 1;77\(5\):1797-1835.](#)

[American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings; AACE Clinical guidelines. Endocr Pract. 2022 May;28\(5\):528-562 7-1835.](#)

